Squamous Cell Cancer

A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
Walter Urba, Bartosz Chmielowski, Deryk Loo, Jan Baughman, Francine Chen, Paul Moore, Ezio Bonvini, James Vasselli, Jon Wigginton, Naiyer Rizvi

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P176; DOI: 10.1186/2051-1426-3-S2-P176
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
Jan Baughman, Deryk Loo, Francine Chen, Paul Moore, Ezio Bonvini, James Vasselli, Jon Wigginton, Roger Cohen

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P177; DOI: 10.1186/2051-1426-3-S2-P177
Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer
Ezra EW Cohen, Kathleen N Moore, Brian M Slomovitz, Christine H Chung, Matthew L Anderson, Shannon R Morris, David Mauro, Barbara Burtness

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P147; DOI: 10.1186/2051-1426-3-S2-P147
An evaluation of autologous tumor-reactive TIL generation from head and neck squamous cell cancers
Tarsem Mougdil, Christopher Paustian, Zipei Feng, Rom Leidner, Christopher Dubay, Brendan D Curti, Hong-Ming Hu, Walter Urba, Carlo Bifulco, Bernard Fox, Brian Bell

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P37; DOI: 10.1186/2051-1426-3-S2-P37

Log in using your username and password

Main menu

Log in using your username and password

You are here

Squamous Cell Cancer